%0 Journal Article
%T The new European Medicines Agency guideline on antidepressants: a guide for researchers and drug developers.
%A Butlen-Ducuing F
%A Haberkamp M
%A Aislaitner G
%A Bałkowiec-Iskra E
%A Mattila T
%A Doucet M
%A Kollb-Sielecka M
%A Balabanov P
%A Leuchs AK
%A Elferink A
%J Eur Psychiatry
%V 67
%N 1
%D 2023 Dec 15
%M 38098366
%F 7.156
%R 10.1192/j.eurpsy.2023.2479
%X According to the World Health Organization (WHO), depressive disorders are currently considered as one of the most disabling medical conditions in the world with one of the highest disability-adjusted life years [1] and this situation has apparently been further worsened during the COVID-19 pandemic [2]. Up to two thirds of patients with major depressive disorders (MDD) do not achieve full remission following an adequate first line standard of care and/or experience residual symptoms such as anxiety, impaired cognition, fatigue, sleep disturbance, or anhedonia [3]. Several attempts are often needed to find the most suitable treatment [4]. Thus, there is a need for medicinal products with better efficacy (e.g., faster onset of action, higher rates of response and remission), improved safety and/or more personalised profiles [5].